673 related articles for article (PubMed ID: 30478418)
21. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
22. Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.
Espinosa D; Mendy J; Manayani D; Vang L; Wang C; Richard T; Guenther B; Aruri J; Avanzini J; Garduno F; Farness P; Gurwith M; Smith J; Harris E; Alexander J
EBioMedicine; 2018 Jan; 27():61-70. PubMed ID: 29269041
[TBL] [Abstract][Full Text] [Related]
23. Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection.
Li A; Xue M; Attia Z; Yu J; Lu M; Shan C; Liang X; Gao TZ; Shi PY; Peeples ME; Boyaka PN; Liu SL; Li J
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554698
[TBL] [Abstract][Full Text] [Related]
24. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
25. Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models.
Guo Q; Chan JF; Poon VK; Wu S; Chan CC; Hou L; Yip CC; Ren C; Cai JP; Zhao M; Zhang AJ; Song X; Chan KH; Wang B; Kok KH; Wen Y; Yuen KY; Chen W
J Infect Dis; 2018 Jul; 218(3):365-377. PubMed ID: 29617816
[TBL] [Abstract][Full Text] [Related]
26. Amphiphilic block copolymer delivery of a DNA vaccine against Zika virus.
Hraber P; Bradfute S; Clarke E; Ye C; Pitard B
Vaccine; 2018 Nov; 36(46):6911-6917. PubMed ID: 30337177
[TBL] [Abstract][Full Text] [Related]
27. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge.
De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH
J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720
[TBL] [Abstract][Full Text] [Related]
28. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
[TBL] [Abstract][Full Text] [Related]
29. A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity.
Zou J; Xie X; Luo H; Shan C; Muruato AE; Weaver SC; Wang T; Shi PY
EBioMedicine; 2018 Oct; 36():92-102. PubMed ID: 30201444
[TBL] [Abstract][Full Text] [Related]
30. Potential targets for therapeutic intervention and structure based vaccine design against Zika virus.
Qadir A; Riaz M; Saeed M; Shahzad-Ul-Hussan S
Eur J Med Chem; 2018 Aug; 156():444-460. PubMed ID: 30015077
[TBL] [Abstract][Full Text] [Related]
31. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
32. Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection.
Yau C; Gan ES; Kwek SS; Tan HC; Ong EZ; Hamis NZ; Rivino L; Chan KR; Watanabe S; Vasudevan SG; Ooi EE
EBioMedicine; 2020 Nov; 61():103028. PubMed ID: 33045466
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine.
Bullard BL; Corder BN; Gorman MJ; Diamond MS; Weaver EA
Sci Rep; 2018 Dec; 8(1):18017. PubMed ID: 30573745
[TBL] [Abstract][Full Text] [Related]
34. Vaccine protection against Zika virus from Brazil.
Larocca RA; Abbink P; Peron JP; Zanotto PM; Iampietro MJ; Badamchi-Zadeh A; Boyd M; Ng'ang'a D; Kirilova M; Nityanandam R; Mercado NB; Li Z; Moseley ET; Bricault CA; Borducchi EN; Giglio PB; Jetton D; Neubauer G; Nkolola JP; Maxfield LF; De La Barrera RA; Jarman RG; Eckels KH; Michael NL; Thomas SJ; Barouch DH
Nature; 2016 Aug; 536(7617):474-8. PubMed ID: 27355570
[TBL] [Abstract][Full Text] [Related]
35. Influence of Dosing Regimen and Adjuvant Type on the Immunogenicity of Novel Recombinant Zika Virus-Like Particles.
Brzuska G; Szewczyk B; Krol E
Microbiol Spectr; 2023 Feb; 11(1):e0288522. PubMed ID: 36541807
[TBL] [Abstract][Full Text] [Related]
36. Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform.
Alvim RGF; Itabaiana I; Castilho LR
Vaccine; 2019 Nov; 37(47):6970-6977. PubMed ID: 31164305
[TBL] [Abstract][Full Text] [Related]
37. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein.
Li A; Yu J; Lu M; Ma Y; Attia Z; Shan C; Xue M; Liang X; Craig K; Makadiya N; He JJ; Jennings R; Shi PY; Peeples ME; Liu SL; Boyaka PN; Li J
Nat Commun; 2018 Aug; 9(1):3067. PubMed ID: 30076287
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a Species E Adenovirus Vector as a Zika virus vaccine.
Bullard BL; Corder BN; Gordon DN; Pierson TC; Weaver EA
Sci Rep; 2020 Feb; 10(1):3613. PubMed ID: 32107394
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.
Sapparapu G; Fernandez E; Kose N; Bin Cao ; Fox JM; Bombardi RG; Zhao H; Nelson CA; Bryan AL; Barnes T; Davidson E; Mysorekar IU; Fremont DH; Doranz BJ; Diamond MS; Crowe JE
Nature; 2016 Dec; 540(7633):443-447. PubMed ID: 27819683
[TBL] [Abstract][Full Text] [Related]
40. Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses.
Tai W; He L; Wang Y; Sun S; Zhao G; Luo C; Li P; Zhao H; Fremont DH; Li F; Jiang S; Zhou Y; Du L
Emerg Microbes Infect; 2018 Jan; 7(1):7. PubMed ID: 29362446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
